Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 112339 | 7.305 |
09:34 ET | 27676 | 7.397 |
09:36 ET | 49582 | 7.514 |
09:38 ET | 36638 | 7.46 |
09:39 ET | 156839 | 7.63 |
09:41 ET | 108622 | 7.45 |
09:43 ET | 53748 | 7.346 |
09:45 ET | 22655 | 7.3008 |
09:48 ET | 16213 | 7.24 |
09:50 ET | 52417 | 7.2501 |
09:52 ET | 17045 | 7.28 |
09:54 ET | 21605 | 7.38 |
09:56 ET | 14775 | 7.48 |
09:57 ET | 26381 | 7.5297 |
09:59 ET | 47175 | 7.54 |
10:01 ET | 42294 | 7.6992 |
10:03 ET | 32113 | 7.58 |
10:06 ET | 22816 | 7.57 |
10:08 ET | 7267 | 7.5 |
10:10 ET | 24179 | 7.485 |
10:12 ET | 7923 | 7.455 |
10:14 ET | 51541 | 7.46 |
10:15 ET | 42408 | 7.3201 |
10:17 ET | 25846 | 7.47 |
10:19 ET | 15272 | 7.43 |
10:21 ET | 4639 | 7.455 |
10:24 ET | 9384 | 7.4 |
10:26 ET | 10141 | 7.35 |
10:28 ET | 7885 | 7.345 |
10:30 ET | 7400 | 7.315 |
10:32 ET | 20277 | 7.415 |
10:33 ET | 4986 | 7.4199 |
10:35 ET | 4301 | 7.415 |
10:37 ET | 14666 | 7.355 |
10:39 ET | 7164 | 7.315 |
10:42 ET | 6932 | 7.325 |
10:44 ET | 9899 | 7.385 |
10:46 ET | 16938 | 7.375 |
10:48 ET | 9354 | 7.35 |
10:50 ET | 7079 | 7.35 |
10:51 ET | 9562 | 7.405 |
10:53 ET | 13446 | 7.395 |
10:55 ET | 10785 | 7.3501 |
10:57 ET | 15457 | 7.33 |
11:00 ET | 10117 | 7.32 |
11:02 ET | 36597 | 7.3999 |
11:04 ET | 21806 | 7.379 |
11:06 ET | 33326 | 7.455 |
11:08 ET | 57644 | 7.52 |
11:09 ET | 11907 | 7.51 |
11:11 ET | 3312 | 7.505 |
11:13 ET | 10066 | 7.475 |
11:15 ET | 6392 | 7.505 |
11:18 ET | 9238 | 7.485 |
11:20 ET | 17382 | 7.58 |
11:22 ET | 31085 | 7.635 |
11:24 ET | 23693 | 7.625 |
11:26 ET | 11431 | 7.605 |
11:27 ET | 14176 | 7.7201 |
11:29 ET | 12413 | 7.71 |
11:31 ET | 33178 | 7.64 |
11:33 ET | 33323 | 7.67 |
11:36 ET | 15708 | 7.655 |
11:38 ET | 5371 | 7.68 |
11:40 ET | 14409 | 7.695 |
11:42 ET | 37326 | 7.7899 |
11:44 ET | 48462 | 7.8201 |
11:45 ET | 23931 | 7.75 |
11:47 ET | 15515 | 7.7028 |
11:49 ET | 14573 | 7.71 |
11:51 ET | 8604 | 7.7048 |
11:54 ET | 30915 | 7.76 |
11:56 ET | 16877 | 7.721 |
11:58 ET | 16730 | 7.79 |
12:00 ET | 31857 | 7.75 |
12:02 ET | 9080 | 7.74 |
12:03 ET | 8282 | 7.7102 |
12:05 ET | 12404 | 7.7101 |
12:07 ET | 48286 | 7.64 |
12:09 ET | 13554 | 7.735 |
12:12 ET | 9072 | 7.7386 |
12:14 ET | 7602 | 7.78 |
12:16 ET | 6341 | 7.77 |
12:18 ET | 43511 | 7.841 |
12:20 ET | 29457 | 7.845 |
12:21 ET | 37297 | 7.8599 |
12:23 ET | 28427 | 7.845 |
12:25 ET | 14713 | 7.86 |
12:27 ET | 8304 | 7.805 |
12:30 ET | 8935 | 7.79 |
12:32 ET | 6284 | 7.78 |
12:34 ET | 9522 | 7.76 |
12:36 ET | 6197 | 7.71 |
12:38 ET | 7381 | 7.75 |
12:39 ET | 17893 | 7.82 |
12:41 ET | 7404 | 7.76 |
12:43 ET | 3194 | 7.76 |
12:45 ET | 7738 | 7.76 |
12:48 ET | 7006 | 7.83 |
12:50 ET | 19172 | 7.835 |
12:52 ET | 14629 | 7.8201 |
12:54 ET | 12992 | 7.775 |
12:56 ET | 8582 | 7.825 |
12:57 ET | 6006 | 7.845 |
12:59 ET | 4918 | 7.8 |
01:01 ET | 9030 | 7.835 |
01:03 ET | 6548 | 7.835 |
01:06 ET | 21810 | 7.855 |
01:08 ET | 15697 | 7.8801 |
01:10 ET | 6200 | 7.87 |
01:12 ET | 36255 | 7.945 |
01:14 ET | 7352 | 7.9149 |
01:15 ET | 24336 | 7.9593 |
01:17 ET | 35486 | 7.97 |
01:19 ET | 12782 | 7.935 |
01:21 ET | 10979 | 7.935 |
01:24 ET | 11148 | 7.915 |
01:26 ET | 29749 | 7.915 |
01:28 ET | 4300 | 7.97 |
01:30 ET | 13721 | 7.9595 |
01:32 ET | 9628 | 7.98 |
01:33 ET | 7619 | 7.93 |
01:35 ET | 7719 | 7.915 |
01:37 ET | 7130 | 7.925 |
01:39 ET | 7484 | 7.935 |
01:42 ET | 6868 | 7.9596 |
01:44 ET | 5356 | 7.935 |
01:46 ET | 7449 | 7.94 |
01:48 ET | 15141 | 7.88 |
01:50 ET | 5191 | 7.865 |
01:51 ET | 5640 | 7.925 |
01:53 ET | 5697 | 7.95 |
01:55 ET | 14916 | 7.99 |
01:57 ET | 8612 | 7.95 |
02:00 ET | 3389 | 7.955 |
02:02 ET | 11941 | 7.9001 |
02:04 ET | 8866 | 7.905 |
02:06 ET | 18721 | 7.965 |
02:08 ET | 2842 | 7.9601 |
02:09 ET | 1546 | 7.955 |
02:11 ET | 16567 | 7.93 |
02:13 ET | 12173 | 7.965 |
02:15 ET | 8697 | 7.96 |
02:18 ET | 12181 | 7.98 |
02:20 ET | 15964 | 8 |
02:22 ET | 40626 | 7.9988 |
02:24 ET | 22692 | 7.93 |
02:26 ET | 14383 | 7.94 |
02:27 ET | 6769 | 7.9103 |
02:29 ET | 24825 | 7.995 |
02:31 ET | 7113 | 8.005 |
02:33 ET | 7738 | 8 |
02:36 ET | 11411 | 8.02 |
02:38 ET | 7833 | 8.025 |
02:40 ET | 10959 | 7.99 |
02:42 ET | 9755 | 7.9966 |
02:44 ET | 10084 | 8.0091 |
02:45 ET | 2048 | 8.01 |
02:47 ET | 2668 | 8.005 |
02:49 ET | 12074 | 7.985 |
02:51 ET | 2346 | 7.99 |
02:54 ET | 9414 | 8.025 |
02:56 ET | 16126 | 7.95 |
02:58 ET | 6948 | 7.96 |
03:00 ET | 14777 | 7.945 |
03:02 ET | 7453 | 7.945 |
03:03 ET | 16330 | 7.97 |
03:05 ET | 13643 | 7.93 |
03:07 ET | 15832 | 7.94 |
03:09 ET | 1628 | 7.94 |
03:12 ET | 3230 | 7.945 |
03:14 ET | 13663 | 7.95 |
03:16 ET | 15380 | 7.9976 |
03:18 ET | 15235 | 7.955 |
03:20 ET | 18569 | 7.9524 |
03:21 ET | 6147 | 7.9329 |
03:23 ET | 23714 | 7.985 |
03:25 ET | 20420 | 8.015 |
03:27 ET | 5734 | 8.015 |
03:30 ET | 14303 | 8.0388 |
03:32 ET | 23667 | 8.0799 |
03:34 ET | 13464 | 8.065 |
03:36 ET | 4773 | 8.0601 |
03:38 ET | 19204 | 8.0401 |
03:39 ET | 24052 | 8.025 |
03:41 ET | 25350 | 8.0201 |
03:43 ET | 8930 | 8.025 |
03:45 ET | 18609 | 8.015 |
03:48 ET | 19662 | 8.01 |
03:50 ET | 20528 | 8.005 |
03:52 ET | 68758 | 7.9799 |
03:54 ET | 35670 | 7.975 |
03:56 ET | 185833 | 7.965 |
03:57 ET | 69536 | 8.0301 |
03:59 ET | 117107 | 8.04 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 6.1B | -48.5x | --- |
Revolution Medicines Inc | 6.3B | -10.8x | --- |
Cytokinetics Inc | 5.6B | -10.1x | --- |
Viking Therapeutics Inc | 6.9B | -63.3x | --- |
BridgeBio Pharma Inc | 5.2B | -8.7x | --- |
Madrigal Pharmaceuticals Inc | 5.0B | -10.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.03 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -48.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.